Other languages Statera Biopharma, Inc.

Equities

STAB

US8575611046

End-of-day quote OTC Markets Other stock markets 03:30:00 17/06/2024 am IST			5-day change	1st Jan Change
0.0006 ^USD	0.00%		0.00%	0.00%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	28/22/28
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/22/21
Statera Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	06/22/06
Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	06/22/06
Statera Biopharma, Inc. Announces Board Changes	09/22/09
Coeptis Therapeutics, Inc. Enters into Termination Agreement with Statera Biopharma, Inc	23/22/23
Coeptis Therapeutics Inc. cancelled the acquisition of TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc..	22/22/22
Involuntary Petition Filed Against Statera Biopharma, Inc.	16/22/16
Statera Biopharma, Inc. Announces Executive Changes	23/22/23
Statera Biopharma's CFO Peter Aronstam Resigns	07/22/07
Statera Biopharma, Inc. Appoints Christopher Zosh as Interim Principal Financial Officer and Principal Accounting Officer	07/22/07
Statera Biopharma Enter Strategic Partnership to License Manufacturing Rights to Certain Lay Sciences IgY Products	13/22/13
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products	13/22/13
Statera Biopharma, Inc. Resignation Cozette M. McAvoy, Chief Legal Officer	28/22/28
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone	28/22/28
Statera Biopharma Strikes Deal With Coeptis Therapeutics for Rights to Entolimod	14/22/14
Statera Biopharma Shares Climb After Agreement to Sell TLR5 Agonist Platform to Coeptis Therapeutics	13/22/13
Statera Biopharma to Sell its TLR5 Agonist Platform to Coeptis Therapeutics	13/22/13
Coeptis Therapeutics, Inc. Enters into Strategic Agreement with Statera Biopharma, Inc	13/22/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Statera Biopharma, Inc.

Equities

STAB

US8575611046

Other languages

Filters